A veteran oncology startup crew is making a very serious bet that they’ve found the key to unlocking the promise of oncolytic viruses
Five years ago, when Amgen ushered the oncolytic virus T-Vec over the finish line at the FDA, 2 things seemed completely clear in short order.
One was that an important new avenue in cancer therapy had been opened up, finding a clean shot at solid tumors while recruiting an immune system attack to “mop up” cancer cell survivors. The other was that any of a number of upstart rivals following that path could do a lot better.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.